Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts

Abstract

PurposeThe transforming growth factor-beta (TGF-β) signaling pathway is known to play a critical role in promoting tumor growth. Consequently, blocking this pathway has been found to inhibit tumor growth. In order to achieve an optimal anti-tumor effect, however, it remains to be established whether blocking the TGF-β signaling pathway alone is sufficient, or whether the tumor microenvironment plays an additional, possibly synergistic, role.MethodsTo investigate the relevance of blocking TGF-β signaling in tumor cells within the context of their respective tissue microenvironments, we treated a panel of patient-derived xenografts (PDX) with the selective TGF-β receptor kinase inhibitor LY2157299 monohydrate (galunisertib) and assessed both the in vitro and in vivo effects.ResultsGalunisertib was found to inhibit the growth in an in vitro clonogenic assay in 6.3 % (5/79) of the examined PDX. Evaluation of the expression profiles of a number of genes, representing both canonical and non-canonical TGF-β signaling pathways, revealed that most PDX exhibited expression changes affecting TGF-β downstream signaling. Next, we subjected 13 of the PDX to an in vivo assessment and, by doing so, observed distinct response patterns. These results suggest that, next to intrinsic, also extrinsic or microenvironmental factors can affect galunisertib response. pSMAD2 protein expression and TGF-βRI mRNA expression levels were found to correlate with the in vivo galunisertib effects.ConclusionsFrom our data we conclude that intrinsic, tumor-dependent TGF-β signaling does not fully explain the anti-tumor effect of galunisertib. Hence, in vivo xenograft models may be more appropriate than in vitro clonogenic assays to assess the anti-tumor activity of TGF-β inhibitors such as galunisertib.Electronic supplementary materialThe online version of this article (doi:10.1007/s13402-014-0210-8) contains supplementary material, which is available to authorized users.

Breast Cancer Cells Respond Differentially to Modulation of TGFβ2 Signaling after Exposure to Chemotherapy or Hypoxia

“…Novel therapies or multidrug regimens that target resistant tumor cell populations may be enabled by recent technological advances, such as nanoparticles, that can enable the timed delivery of two different compounds (48). Our data have specific implications for the development of TGFb pathway modulators such as type 1 TGFb receptor inhibitors (49,50). In addition, our results suggest that microenvironment-based biomarkers might be valuable complements to tumor cell-based biomarkers in optimizing the design of therapeutic regimens.…”

Inhibition of hesperidin on epithelial to mesenchymal transition of non-small cell lung cancer cells induced by TGF-Beta1

“…2,3 Although chemotherapy is applied for treating NSCLC, the effect of treatment is poor due to serious toxicities. 4,5 Therefore, some studies have paid attention to natural molecules or extracts which made from leaves, seeds, flowers, fruits, barks and roots, expecting to find out ideal anti-NSCLC drugs with non-toxic or low-toxic, cost-effective and physiologically available character.…”

Anti-proliferative, apoptotic and signal transduction effects of hesperidin in non-small cell lung cancer cells

“…NSCLC accounts for~80 % of all lung cancer cases, with adenocarcinoma being the primary subtype [3]. NSCLC is less responsive to chemotherapy than SCLC and, as a consequence, NSCLC is the main focus of current research through which several new therapeutic drugs are being investigated [4][5][6]. The overall prognosis of lung cancer is poor, which is primarily due to the fact that the diagnosis is frequently made late and/or at an advanced stage [7].…”

“…The overall prognosis of lung cancer is poor, which is primarily due to the fact that the diagnosis is frequently made late and/or at an advanced stage [7]. Although 70 % of the newly diagnosed patients present with locally advanced or metastatic lung cancers that require systemic treatment, currently available systemic chemotherapies and molecular targeted therapies have their limitations due to dosedependent toxicities and the acquisition of drug resistancies [6][7][8]. In order to develop novel effective treatment strategies for lung cancer, several recent studies have been focusing on dietary agents including nutraceuticals, which are non-toxic, cost-effective and physiologically available [9][10][11].…”